- Home
- HDL vs OCS Comparison
HDL vs OCS Comparison
Compare HDL & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HDL
- OCS
- Stock Information
- Founded
- HDL 2016
- OCS 2003
- Country
- HDL Singapore
- OCS Switzerland
- Employees
- HDL N/A
- OCS N/A
- Industry
- HDL Restaurants
- OCS Biotechnology: Pharmaceutical Preparations
- Sector
- HDL Consumer Discretionary
- OCS Health Care
- Exchange
- HDL Nasdaq
- OCS Nasdaq
- Market Cap
- HDL 1.1B
- OCS 869.8M
- IPO Year
- HDL 2024
- OCS N/A
- Fundamental
- Price
- HDL $17.66
- OCS $21.09
- Analyst Decision
- HDL
- OCS Strong Buy
- Analyst Count
- HDL 0
- OCS 4
- Target Price
- HDL N/A
- OCS $41.00
- AVG Volume (30 Days)
- HDL 745.0
- OCS 82.6K
- Earning Date
- HDL 11-24-2025
- OCS 11-06-2025
- Dividend Yield
- HDL N/A
- OCS N/A
- EPS Growth
- HDL 197.81
- OCS N/A
- EPS
- HDL 0.09
- OCS N/A
- Revenue
- HDL $805,433,000.00
- OCS $960,668.00
- Revenue This Year
- HDL $11.57
- OCS $38.85
- Revenue Next Year
- HDL $12.00
- OCS $994.06
- P/E Ratio
- HDL $21.22
- OCS N/A
- Revenue Growth
- HDL 9.65
- OCS N/A
- 52 Week Low
- HDL $15.54
- OCS $14.00
- 52 Week High
- HDL $30.00
- OCS $23.08
- Technical
- Relative Strength Index (RSI)
- HDL 40.50
- OCS 64.07
- Support Level
- HDL $17.51
- OCS $20.96
- Resistance Level
- HDL $18.38
- OCS $21.94
- Average True Range (ATR)
- HDL 0.20
- OCS 0.77
- MACD
- HDL -0.01
- OCS 0.01
- Stochastic Oscillator
- HDL 11.59
- OCS 73.70
About HDL SUPER HI INTERNATIONAL HOLDING LTD. American Depositary Shares
Super Hi International Holding Ltd is an investment holding company and its subsidiaries are principally engaged in restaurant operations, delivery business, and sales of hot pot condiment products and food ingredients located in the overseas market outside Mainland China, Hong Kong, Macau, and Taiwan. It mission is to become a global integrated restaurant group, build the world's Chinese cuisine brand, and promote Chinese culinary heritage world-wide.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.